Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury
Vassilios J. Bezzerides, Colin Platt, Carolin Lerchenmüller, Kaavya Paruchuri, Nul Loren Oh, Chunyang Xiao, Yunshan Cao, Nina Mann, Bruce M. Spiegelman, Anthony Rosenzweig
Vassilios J. Bezzerides, Colin Platt, Carolin Lerchenmüller, Kaavya Paruchuri, Nul Loren Oh, Chunyang Xiao, Yunshan Cao, Nina Mann, Bruce M. Spiegelman, Anthony Rosenzweig
View: Text | PDF
Research Article Cardiology

CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury

  • Text
  • PDF
Abstract

The mechanisms by which exercise mediates its multiple cardiac benefits are only partly understood. Prior comprehensive analyses of the cardiac transcriptional components and microRNAs dynamically regulated by exercise suggest that the CBP/p300-interacting protein CITED4 is a downstream effector in both networks. While CITED4 has documented functional consequences in neonatal cardiomyocytes in vitro, nothing is known about its effects in the adult heart. To investigate the impact of cardiac CITED4 expression in adult animals, we generated transgenic mice with regulated, cardiomyocyte-specific CITED4 expression. Cardiac CITED4 expression in adult mice was sufficient to induce an increase in heart weight and cardiomyocyte size with normal systolic function, similar to the effects of endurance exercise training. After ischemia-reperfusion, CITED4 expression did not change initial infarct size but mediated substantial functional recovery while reducing ventricular dilation and fibrosis. Forced cardiac expression of CITED4 also induced robust activation of the mTORC1 pathway after ischemic injury. Moreover, pharmacological inhibition of mTORC1 abrogated CITED4’s effects in vitro and in vivo. Together, these data establish CITED4 as a regulator of mTOR signaling that is sufficient to induce physiologic hypertrophy at baseline and mitigate adverse ventricular remodeling after ischemic injury.

Authors

Vassilios J. Bezzerides, Colin Platt, Carolin Lerchenmüller, Kaavya Paruchuri, Nul Loren Oh, Chunyang Xiao, Yunshan Cao, Nina Mann, Bruce M. Spiegelman, Anthony Rosenzweig

×

Figure 3

CITED4 improves cardiac remodeling after ischemia/reperfusion injury.

Options: View larger image (or click on image) Download as PowerPoint
CITED4 improves cardiac remodeling after ischemia/reperfusion injury.
(A...
(A) No change in infarct size at 24 hours after ischemia reperfusion injury (IRI) from transient ligation of the left anterior descending artery (LAD) as demonstrated by TTC staining. (B) Noninvasive assessment of ventricular function demonstrates substantial dysfunction at 24 hours after IRI that improves significantly over time in the iCITED4 transgenics but not controls. n ≥ 5 mice per group per time point for analysis. **P < 0.01. (C) Representative micrographs of cardiac sections stained with MTS demonstrating a reduction of fibrosis in iCITED4 transgenics 4 weeks after IRI. High-magnification inlays demonstrate area of fibrosis and myocyte loss. Scale bar: 200 μm. (D) Quantification of fibrosis as a percentage of the total area (Control: 11.9% ± 2.6%, iCITED4: 3.5% ± 1.2%, n = 5 per group). **P < 0.01. (E) Trend to reduced lung weights consistent with a decreased degree of heart failure in CITED4 expressing mice, †P = 0.06 by Student’s t test. (F) Improvement in mortality in iCITED4 transgenics as compared with controls; n = 13 (control), 11 (iCITED4) at the start of the experiment; P < 0.05 by Log-Rank parametric test. For all graphs: significance determined by the Student’s t test unless otherwise specified; *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts